FOLH1 and metastatic prostate carcinoma: The initial results demonstrated that radionuclide therapy with 177Lu-PSMA-TUM1 is both safe and effective in castrate-resistant metastatic prostate cancer with appropriate selection and follow-up of patients by 68Ga-PSMA-HBED-CC PET/CT (Fig. 26), making PSMA an excellent target for both diagnostic imaging and radiotherapeutic approaches.